Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.

Fiche publication


Date publication

janvier 2020

Journal

Therapeutic advances in medical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier, Pr GHIRINGHELLI François, Mme JACQUIN Marion, Dr VERNEREY Dewi, Dr KAMINSKY Marie-Christine, Dr KIM Stephano, Dr LAKKIS Zaher, Mme MEURISSE Aurélia


Tous les auteurs :
Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C

Résumé

The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in advanced squamous cell carcinoma of the anus (SCCA). Preliminary results of Epitopes-HPV01 study showed a high rate of long-lasting complete response to DCF. The prospective, multicenter, Epitopes-HPV02 trial then confirmed the high efficacy of the modified DCF (mDCF) regimen in terms of complete response rate and long-term survival in metastatic or non-resectable locally advanced recurrent SCCA. Here, we present updated results of the Epitopes-HPV01 and Epitopes-HPV02 studies.

Mots clés

advanced, anal squamous cell carcinoma, chemotherapy, docetaxel, metastatic

Référence

Ther Adv Med Oncol. 2020 ;12:1758835920975356